Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY CEA Expansion, Higher Copay Likely to Be Included in Minister Budget Deal
December 24, 2024
-
COMMENTARY Where Do Japan Drug Makers Stand? A Comparison with Other Industries and Mega Pharma Peers
December 24, 2024
-
REGULATORY Off-Year Price Revision to Hit 53% of Listed Drugs in 2025, Down from 69%
December 23, 2024
-
REGULATORY Three Ministers Agree on Off-Year Drug Price Revision in FY2025
December 20, 2024
-
REGULATORY Japan Set to Settle Off-Year Debate with “x1.0” Threshold for PMP Meds/Generics, “x0.5” for LLPs
December 20, 2024
-
REGULATORY Japan Weighs Tweaking “x0.625” Threshold to Narrow Off-Year Revision Coverage
December 19, 2024
-
REGULATORY Japan to Add Shingles Vaccines to NIP List from FY2025, Targeting Age 65
December 19, 2024
-
ORGANIZATION JPA Calls for Improving Package Units as Pharmacies Suffer with Unsold Stocks of Pricey Meds
December 19, 2024
-
BUSINESS Jazz’s Epilepsy Drug Candidate Nearing Submission as Japan Lifts Ban on Cannabis-Derived Meds
December 18, 2024
-
REGULATORY Ruling Bloc’s Draft Budget Policy Says Off-Year Revisions Could Alter, but DPP Calls for Explicit Mention of Repeal
December 17, 2024
-
BUSINESS Takeda Sees Up to US$20 Billion Sales Potential with 6 Late-Stage Assets
December 16, 2024
-
BUSINESS Amgen Japan Marks “Significant Milestone” with Tepezza Release, Eyes More Launches
December 16, 2024
-
REGULATORY LDP’s Tamura Renews Question over Product Coverage of Off-Year Revisions
December 16, 2024
-
COMMENTARY Battle over Off-Year Price Revision Now Heading for Political Settlement
December 13, 2024
-
REGULATORY CDP OKs Bill to Scrap Off-Year Revisions, Aims for Diet Submission Soon
December 13, 2024
-
REGULATORY Hearing Leaves Chuikyo Mixed on Off-Year Scheme, Political Decision Ever More Likely
December 12, 2024
-
BUSINESS ViiV to Hone In on Long-Acting Treatments for HIV: Japan President
December 11, 2024
-
REGULATORY LDP Study Group Urges Health, Finance Ministers to Drop Off-Year Revisions
December 11, 2024
-
BUSINESS Off-Year Re-Pricing Will Ruin Investment Momentum: BMS Japan Chief
December 10, 2024
-
REGULATORY PM Ishiba Takes Note of Opposition Party’s Plea for Scrapping Off-Year Revisions
December 9, 2024
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…